Tempe, Arizona, USA, September 2, 2026
GT Medical Technologies has announced Renown Regional Medical Center as the latest institution to receive a GammaTile® Center of Excellence Program designation, recognizing its expertise in delivering GammaTile therapy for patients with brain tumors. The designation acknowledges healthcare institutions and physicians that demonstrate advanced clinical capabilities in the GammaTile procedure, while meeting defined clinical criteria, annual case-volume requirements and continuing education standards. The program is intended to recognize centers demonstrating a strong commitment to patient education, clinical expertise and advanced brain-tumor care. The latest designation brings six physicians at Renown Regional Medical Center into the program: Suchit Patel, MD, PhD, and Garrett Green, MD, from Radiation Oncology, along with Rima Rindler, MD, Angelique Tay, MD, Michael Moore, MD, and Chris Demers, MD, from Neurosurgery. The development highlights the growing use of specialized medical-device-based radiation therapy in the management of complex intracranial tumors.
GammaTile Center Recognizes Advanced Clinical Expertise
The GammaTile Center of Excellence Program is designed to recognize physicians and institutions that demonstrate established expertise in using GammaTile during brain-tumor surgery. Participating centers must meet specific clinical criteria, annual case minimums and ongoing education requirements, creating a structured framework for recognizing experience with the technology. Renown Regional Medical Center’s new designation therefore reflects not simply access to GammaTile, but the institution’s demonstrated clinical experience and commitment to maintaining expertise in the procedure. The physicians recognized through the program represent both neurosurgery and radiation oncology, reflecting the multidisciplinary nature of GammaTile treatment. Such collaboration is particularly important in brain-tumor care because treatment decisions can involve tumor removal, radiation therapy, imaging, neurological considerations and long-term patient management. The Center of Excellence model emphasizes coordinated expertise around the GammaTile procedure while also supporting patient education and continued professional development. Dr. Suchit Patel, a radiation oncologist at Renown Regional Medical Center, described the designation as a significant milestone for the institution and its patients. He highlighted the ability to provide advanced treatment locally, allowing patients in the surrounding community to access specialized brain-tumor treatment without necessarily traveling to a distant major medical center.
GammaTile Delivers Radiation During Tumor Surgery
GammaTile is an FDA-cleared, bioabsorbable collagen implant embedded with radiation seeds. The device is placed directly into the surgical cavity at the time of brain-tumor removal, allowing radiation to be delivered locally at the tumor site. This approach differs from conventional external radiation strategies that may require a waiting period after surgery before radiation treatment begins. The technology is designed to provide immediate, localized radiation to areas where residual tumor cells may remain following surgical resection. By positioning the radiation source directly within the surgical cavity, GammaTile is intended to target remaining cancer cells while limiting radiation exposure to surrounding healthy brain tissue. The treatment approach is particularly relevant in situations where minimizing the interval between tumor removal and postoperative radiation may be clinically important. According to GT Medical Technologies, GammaTile is authorized for commercial distribution in the United States for patients with newly diagnosed malignant intracranial neoplasms and recurrent intracranial neoplasms. The device received FDA clearance as a bioabsorbable implant designed to deliver radiation locally following tumor removal, positioning it within the growing field of implantable radiation technologies and advanced medical devices for oncology.
Advertisement
GT Medical Technologies Expands GammaTile Adoption
The new Center of Excellence designation comes as GammaTile continues to expand across U.S. healthcare institutions. GT Medical Technologies reports that the technology has been adopted by more than 100 leading centers since its full U.S. market launch in March 2020, including both academic and community healthcare settings. The expansion demonstrates how specialized medical technologies can move beyond regulatory authorization toward broader implementation through clinical training, physician expertise and institutional quality programs. Establishing experienced treatment centers can be particularly important for advanced surgical technologies because appropriate patient selection, procedural technique and multidisciplinary coordination can influence the successful integration of a device into clinical practice. For cGxP.wire readers, the development is significant from a MedTech, medical-device and oncology-care perspective. GammaTile combines surgery and localized radiation delivery within a single treatment strategy, while the Center of Excellence program emphasizes clinical competency and continuing education. The latest designation at Renown Regional Medical Center also illustrates the role of structured clinical programs in supporting the responsible adoption of FDA-cleared medical technologies. As GammaTile adoption continues across the United States, the Center of Excellence program may provide an additional framework for recognizing institutions with substantial experience in the procedure. The initiative underscores the importance of clinical expertise, patient education, multidisciplinary care and ongoing training alongside medical-device innovation in advancing treatment options for patients with complex brain tumors.
Source: GT Medical Technologies, GammaTile press release
